Scotland rejects five products for use in the region's NHS
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium declined to recommend five products for use in the region's national health service earlier this month, including GlaxoSmithKline's anticancer Tyverb (lapatinib) and Tibotec's (Janssen-Cilag) AIDS drug Intelence (etravirine).